Use of bisphosphonates in patients with myeloma and renal failure.
Saghafi
Darius
D
D000970:Antineoplastic Agents; D016723:Bone Remodeling / Q000187:drug effects; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000150:complications* / Q000503:physiopathology; D000075202:Contraindications; D004164:Diphosphonates; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000503:physiopathology; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D000077268:Pamidronate
D000970:Antineoplastic Agents; D004164:Diphosphonates; D000077268:Pamidronate